期刊
PLOS ONE
卷 17, 期 11, 页码 -出版社
PUBLIC LIBRARY SCIENCE
DOI: 10.1371/journal.pone.0276781
关键词
-
资金
- Cambridge BHF CRE non-clinical PhD studentship
- Innovative Medicines Initiative-2 Joint Undertaking [116074]
- BHF-Turing Cardiovascular Data Science Award [BCDSA\100005]
- UK MRC [MR/L003120/1]
- BHF [RG/13/13/30194, RG/18/13/33946]
- NIHR Cambridge Biomedical Research Centre [BRC-1215-20014]
- Biomedical Research Centre Award
- NIHR Applied Research Collaboration (ARC) West
Hypertension is an important risk factor for severe COVID-19. Individuals with hypertension have a higher risk of developing severe COVID-19 compared to those without hypertension. The level of systolic blood pressure and the type of anti-hypertensive medication used are also related to the risk of severe COVID-19.
Hypertension appears to be one of the commonest comorbidities in COVID-19 patients, although whether hypertensive individuals have a higher risk of severe COVID-19 compared with non-hypertensives is unclear. It is also unclear whether the absolute level of systolic blood pressure, or the type of anti-hypertensive medication is related to this risk. Analyses were conducted using data from the UK Biobank and linked health records. Logistic regression models were fitted to assess the impact of hypertension, systolic blood pressure (SBP) and medications on the risk of severe COVID-19. 16,134 individuals tested positive for severe acute respiratory syndrome-coronavirus, 22% (n = 3,584) developed severe COVID-19 and 40% (n = 6,517) were hypertensive. Hypertension was associated with 22% higher odds of severe COVID-19 (Odds ratio (OR) 1.22; 95% confidence interval (CI) 1.12, 1.33), compared with normotension after adjusting for confounding variables. In those taking anti-hypertensive medications, elevated SBP showed a dose-response relationship with severe COVID-19 (150-159mmHg versus 120-129mmHg (OR 1.91; 95% CI 1.44, 2.53), >180+mmHg versus 120-129mmHg (OR 1.93; 95% CI 1.06, 3.51)). SBP <120mmHg was associated with greater odds of severe COVID-19 (OR 1.40; 95% CI 1.11, 1.78). Angiotensin-converting enzyme inhibitors or angiotensin-II receptor blockers were not associated with altered risk of severe COVID-19. Hypertension is an important risk factor for COVID-19. A better understanding of the underlying mechanisms is warranted in case of more severe strains or other viruses in the future.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据